002550 千红制药
已收盘 06-24 15:00:00
资讯
新帖
简况
千红制药涨9.97%，东海证券一个月前给出“买入”评级
证券之星 · 06-24 16:44
千红制药涨9.97%，东海证券一个月前给出“买入”评级
6月24日千红制药（002550）涨停分析：可转债获批、产业链落地、创新药进展驱动
证券之星 · 06-24 15:42
6月24日千红制药（002550）涨停分析：可转债获批、产业链落地、创新药进展驱动
异动快报：千红制药（002550）6月24日9点43分触及涨停板
证券之星 · 06-24 09:45
异动快报：千红制药（002550）6月24日9点43分触及涨停板
股市必读：千红制药（002550）6月17日董秘有最新回复
证券之星 · 06-18
股市必读：千红制药（002550）6月17日董秘有最新回复
千红制药：如未能在回购股份后的36个月内实施完毕，未使用部分将依法依规履行注销程序
证券之星 · 06-17
千红制药：如未能在回购股份后的36个月内实施完毕，未使用部分将依法依规履行注销程序
千红制药：公司近年内已多次实施股份回购方案
证券之星 · 06-08
千红制药：公司近年内已多次实施股份回购方案
千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务
证券之星 · 06-03
千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务
千红制药：公司原创一类新药QHRD106项目正处于有序推进临床试验阶段
证券之星 · 06-03
千红制药：公司原创一类新药QHRD106项目正处于有序推进临床试验阶段
股市必读：千红制药（002550）6月1日董秘有最新回复
证券之星 · 06-02
股市必读：千红制药（002550）6月1日董秘有最新回复
千红制药：QHRD106项目正处于科学有序地推进临床试验进程中
证券之星 · 06-01
千红制药：QHRD106项目正处于科学有序地推进临床试验进程中
千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务
证券之星 · 05-27
千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务
千红制药：公司创新药QHRD106项目正处于有序推进临床试验阶段
证券之星 · 05-27
千红制药：公司创新药QHRD106项目正处于有序推进临床试验阶段
千红制药：公司创新药项目均严格按照国家药品注册法规要求推进临床试验
证券之星 · 05-25
千红制药：公司创新药项目均严格按照国家药品注册法规要求推进临床试验
千红制药：公司可转债项目已获深交所受理
证券之星 · 05-25
千红制药：公司可转债项目已获深交所受理
千红制药：公司可转债项目于2026年2月12日收到审核问询函
证券之星 · 05-25
千红制药：公司可转债项目于2026年2月12日收到审核问询函
股市必读：千红制药（002550）5月22日董秘有最新回复
证券之星 · 05-25
股市必读：千红制药（002550）5月22日董秘有最新回复
转型阵痛中的千红制药：肝素原料药周期冲击业绩，创新药远水难解近渴
市场资讯 · 05-24
转型阵痛中的千红制药：肝素原料药周期冲击业绩，创新药远水难解近渴
股市必读：千红制药（002550）5月20日董秘有最新回复
证券之星 · 05-21
股市必读：千红制药（002550）5月20日董秘有最新回复
转型阵痛中的千红制药：肝素原料药周期冲击一季度业绩，创新药远水难解近渴
证券之星 · 05-20
转型阵痛中的千红制药：肝素原料药周期冲击一季度业绩，创新药远水难解近渴
千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中
证券之星 · 05-20
千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中
加载更多
公司概况
公司名称：
常州千红生化制药股份有限公司
所属行业：
医药制造业
上市日期：
2011-02-18
主营业务：
常州千红生化制药股份有限公司的主营业务是生物医药品的研发、生产和销售。公司的主要产品是常生千红、千红怡诺、千红怡达、千红怡那、怡开、千红怡美、常生、千红怡甘。
发行价格：
32.00
{"stockData":{"symbol":"002550","market":"SZ","secType":"STK","nameCN":"千红制药","latestPrice":6.51,"timestamp":1782284631000,"preClose":5.92,"halted":0,"volume":39876253,"delay":0,"changeRate":0.0997,"floatShares":941000000,"shares":1280000000,"eps":0.2523,"marketStatus":"已收盘","change":0.59,"latestTime":"06-24 15:00:00","open":5.96,"high":6.51,"low":5.88,"amount":255000000,"amplitude":0.1064,"askPrice":0,"askSize":0,"bidPrice":6.51,"bidSize":60032,"shortable":0,"etf":0,"ttmEps":0.2523,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782351000000},"marketStatusCode":5,"adr":0,"adjPreClose":5.92,"symbolType":"stock","openAndCloseTimeList":[[1782264600000,1782271800000],[1782277200000,1782284400000]],"highLimit":6.51,"lowLimit":5.33,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1279800000,"isCdr":false,"pbRate":2.65,"roa":"--","peRate":25.802616,"roe":"3.03%","epsLYR":0.32,"committee":0,"marketValue":8331000000,"turnoverRate":0.0424,"status":0,"floatMarketCap":6127000000},"requestUrl":"/m/hq/s/002550","defaultTab":"news","newsList":[{"id":"2645174895","title":"千红制药涨9.97%，东海证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2645174895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645174895?lang=zh_cn&edition=full","pubTime":"2026-06-24 16:44","pubTimestamp":1782290687,"startTime":"0","endTime":"0","summary":"今日千红制药涨9.97%，收盘报6.51元。2026年5月8日，东海证券研究员杜永宏,付婷发布了对千红制药的研报《公司简评报告：业绩短期放缓，期待创新转型成果》，该研报对千红制药给出“买入”评级。公司主营业务整体稳健，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为平安证券的臧文清。千红制药个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400030225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645898971","title":"6月24日千红制药（002550）涨停分析：可转债获批、产业链落地、创新药进展驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2645898971","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645898971?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:42","pubTimestamp":1782286954,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药6月24日涨停收盘，收盘价6.51元。6月24日千红制药涨停的可能因素有：可转债发行获深交所审核通过，仅待注册，募资将投向产能扩张与创新药研发；河南千牧基地已投产、湖北原料药基地即将完工，自产原料药年降本超4700万元；研发投入同比增超280%，4款创新药进入II期及以上临床；2025年归母净利润同比增长12%，连续两年双位数增长，历史信托纠纷彻底结案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400023680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550","BK1574","159992","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645637058","title":"异动快报：千红制药（002550）6月24日9点43分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2645637058","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645637058?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:45","pubTimestamp":1782265531,"startTime":"0","endTime":"0","summary":"证券之星6月24日盘中消息，9点43分千红制药（002550）触及涨停板。其所属行业化学制药目前上涨。领涨股为海南海药。该股为创新药，化学原料药，医药概念热股，当日创新药概念上涨1.49%，化学原料药概念上涨1.05%，医药概念上涨0.84%。6月23日的资金流向数据方面，主力资金净流出527.5万元，占总成交额4.17%，游资资金净流出194.17万元，占总成交额1.53%，散户资金净流入721.67万元，占总成交额5.7%。近5日资金流向一览见下表：千红制药主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400010864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644724973","title":"股市必读：千红制药（002550）6月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644724973","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644724973?lang=zh_cn&edition=full","pubTime":"2026-06-18 04:59","pubTimestamp":1781729947,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，千红制药报收于5.78元，下跌0.69%，换手率0.96%，成交量9.08万手，成交额5214.61万元。董秘最新回复投资者： 董秘，您好！董秘： 尊敬的投资者，您好，公司近年内已多次实施股份回购方案，按深交所及证监会相关法规，如未能在回购股份后的36个月内实施完毕，未使用部分将依法依规履行注销程序。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800004066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644282746","title":"千红制药：如未能在回购股份后的36个月内实施完毕，未使用部分将依法依规履行注销程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2644282746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644282746?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:48","pubTimestamp":1781700523,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)06月17日在投资者关系平台上答复投资者关心的问题。投资者提问：公司为什么不把回购的股票直接注销？公司现任的管理层根本不值得进行股权奖励？千红制药回复：尊敬的投资者，您好，公司近年内已多次实施股份回购方案，按深交所及证监会相关法规，如未能在回购股份后的36个月内实施完毕，未使用部分将依法依规履行注销程序。感谢您对公司的关注与建议。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700039285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148440","title":"千红制药：公司近年内已多次实施股份回购方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641148440?lang=zh_cn&edition=full","pubTime":"2026-06-08 20:48","pubTimestamp":1780922897,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)06月08日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，根据公司年报分析，现阶段公司可使用现金流达到12亿左右，也不存在大额偿账压力，为什么不采取股票回购注销行动进行市值管理，难道公司自己也认为当前股价虚高不值得回购？千红制药回复：尊敬的投资者，您好，公司近年内已多次实施股份回购方案，用于实施员工持股计划或股权激励，按深交所及证监会相关法规，如未能在回购股份后的36个月内实施完毕，未使用部分将依法依规履行注销程序。感谢您对公司的关注与建议。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800032854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640595971","title":"千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2640595971","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640595971?lang=zh_cn&edition=full","pubTime":"2026-06-03 15:04","pubTimestamp":1780470262,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘:公司在2.10收到问询函为什么没有及时如实发布公布呢？为什么和去年9月公司高层越线买入股票同出一辙呢？千红制药回复：尊敬的投资者，您好，公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务，依据监管要求进行了科学合理的工作推进安排并及时公告，不存在应披露未披露的情况。感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300025592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640718069","title":"千红制药：公司原创一类新药QHRD106项目正处于有序推进临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2640718069","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640718069?lang=zh_cn&edition=full","pubTime":"2026-06-03 15:03","pubTimestamp":1780470192,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘请问:公司的106创新药在什么日期获得CDE批准进行二期b临床的批文也不属于重大机密为什么不敢明确告知呢？千红制药回复：尊敬的投资者，您好，公司须严格按照证监会和交易所的相关规定履行信息披露义务，公司原创一类新药QHRD106项目正处于有序推进临床试验阶段，相关进展将严格遵循法规披露要求。感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300025538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640041969","title":"股市必读：千红制药（002550）6月1日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640041969","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640041969?lang=zh_cn&edition=full","pubTime":"2026-06-02 02:54","pubTimestamp":1780340051,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，千红制药报收于6.33元，上涨0.0%，换手率1.11%，成交量10.44万手，成交额6600.04万元。投资者： 董秘:请正面回复106创新药获得CDE批准进行二期b临床增补数据的日期？董秘： 尊敬的投资者，您好，公司原创一类新药QHRD106项目正处于科学有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200002222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640195435","title":"千红制药：QHRD106项目正处于科学有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2640195435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640195435?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:48","pubTimestamp":1780318091,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)06月01日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘请问:公司在2025中期报告和可转换债券募集书、2025年报中关于106创新药的实际临床进度的前后不一，已经是事实上违反了《证券法》第84条:信息披露义务人披露信息应当真实、准确、完整要求？千红制药回复：尊敬的投资者，您好，公司严格按照证监会和交易所的相关规定履行信息披露义务，不存在应披露未披露的重大事项。公司原创一类新药QHRD106项目正处于科学有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100037897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638735555","title":"千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2638735555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638735555?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:36","pubTimestamp":1779853004,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问:公司收到交易所关于申请发行可转换债券问询函是属于重大事项？为什么没有发布收到该问询函的公告？千红制药回复：尊敬的投资者，您好，公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务，依据相关监管要求进行了科学合理的工作推进安排并及时公告。感谢您的关注。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638573568","title":"千红制药：公司创新药QHRD106项目正处于有序推进临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2638573568","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638573568?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:36","pubTimestamp":1779853004,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司的创新药106是在什么时候获得CDE批准进行二期b补充验证临床试验的？千红制药回复：公司创新药QHRD106项目正处于有序推进临床试验阶段，相关进展请关注公司后续公告，感谢您的关注。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","002550","06978","BK1161","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638535038","title":"千红制药：公司创新药项目均严格按照国家药品注册法规要求推进临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2638535038","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638535038?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:18","pubTimestamp":1779697093,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘请正面回答公司可转债申报阶段是否知道创新药106要进行增补验证？千红制药回复：尊敬的投资者，您好，公司创新药项目均严格按照国家药品注册法规要求推进临床试验，相关进展将依法依规履行披露义务，感谢您的关注。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500021658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","06978","BK1574","002550","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638535033","title":"千红制药：公司可转债项目已获深交所受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2638535033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638535033?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:18","pubTimestamp":1779697093,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的可转换债券审核进度是否异常千红制药回复：尊敬的投资者，您好，公司可转债项目已获深交所受理，并于2026年2月12日收到审核问询函，公司已于3月10日完成回复并公告。目前该项目正在有序推进中，后续进展将依法依规及时披露。感谢您的关注。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500021659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638350805","title":"千红制药：公司可转债项目于2026年2月12日收到审核问询函","url":"https://stock-news.laohu8.com/highlight/detail?id=2638350805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638350805?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:18","pubTimestamp":1779697090,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司近期有没有收到交易所二次问询函？千红制药回复：尊敬的投资者，您好，公司可转债项目于2026年2月12日收到审核问询函，公司已于3月10日完成回复并公告。目前该项目正在有序推进中，后续进展将依法依规及时披露。感谢您的关注。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500021649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638304665","title":"股市必读：千红制药（002550）5月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2638304665","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638304665?lang=zh_cn&edition=full","pubTime":"2026-05-25 01:56","pubTimestamp":1779645372,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，千红制药报收于6.59元，上涨1.85%，换手率1.3%，成交量12.27万手，成交额8019.92万元。来自公司公告汇总：千红制药将于2026年5月29日实施除权除息，每10股派发现金红利1.5元（含税）。公司公告汇总千红制药：2025年度权益分派实施公告常州千红生化制药股份有限公司2025年度权益分派方案为：以公司总股本1,279,800,000股剔除回购专用账户中库存股18,000,000股后的1,261,800,000股为基数，向全体股东每10股派发现金红利1.5元（含税）。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500000818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637491308","title":"转型阵痛中的千红制药：肝素原料药周期冲击业绩，创新药远水难解近渴","url":"https://stock-news.laohu8.com/highlight/detail?id=2637491308","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637491308?lang=zh_cn&edition=full","pubTime":"2026-05-24 15:00","pubTimestamp":1779606000,"startTime":"0","endTime":"0","summary":" 作为国内少数涵盖肝素全产业链的生化药企，千红制药在经历了2022年的营收峰值后，连续两年下滑，2025年借低基数实现微弱反弹，却远未恢复至历史高点。进入2026年一季度，出口肝素原料药遭遇全球需求疲软与合同发货周期的双重打击，公司营收与归属净利润再度双双大幅下挫。 证券之星注意到，被千红制药寄予厚望的创新药“第二曲线”仍处于临床阶段，距离商业化贡献业绩尚需时日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-05-24/doc-inhyytnm5942974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","06978","BK1161","159992","002550","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637878700","title":"股市必读：千红制药（002550）5月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2637878700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637878700?lang=zh_cn&edition=full","pubTime":"2026-05-21 04:14","pubTimestamp":1779308092,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，千红制药报收于6.57元，下跌2.67%，换手率1.84%，成交量17.36万手，成交额1.14亿元。董秘： 尊敬的投资者，您好，根据公司2025年11月披露的可转债项目相关公告，公司原创一类新药QHRD106注射液三期临床研究及上市注册项目为本次可转债募投项目之一，该项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100004952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636581718","title":"转型阵痛中的千红制药：肝素原料药周期冲击一季度业绩，创新药远水难解近渴","url":"https://stock-news.laohu8.com/highlight/detail?id=2636581718","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636581718?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:00","pubTimestamp":1779267644,"startTime":"0","endTime":"0","summary":"进入2026年一季度，出口肝素原料药遭遇全球需求疲软与合同发货周期的双重打击，公司营收与归属净利润再度双双大幅下挫。2023年财报中，千红制药曾坦言，肝素原料药面临下游企业去库存、需求大幅下滑导致出口价格与数量均显著下降，行业整体受到较大冲击。对于肝素主业与创新药业务之间的战略重心如何平衡，千红制药回应称，未来将加大重大创新药物的研发与上市节奏，使之成为公司业务增长的新的战略核心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026052000030426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","06978","BK1574","002550","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636892475","title":"千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2636892475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636892475?lang=zh_cn&edition=full","pubTime":"2026-05-20 11:36","pubTimestamp":1779248185,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药05月20日在投资者关系平台上答复投资者关心的问题。公司创新药项目均处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000019084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","159992","BK1574","06978","002550"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782318032523,"stockEarnings":[{"period":"1week","weight":0.1263},{"period":"1month","weight":0.0162},{"period":"3month","weight":-0.0701},{"period":"6month","weight":-0.1603},{"period":"1year","weight":-0.2526},{"period":"ytd","weight":-0.1518}],"compareEarnings":[{"period":"1week","weight":0.0007},{"period":"1month","weight":-0.0101},{"period":"3month","weight":0.057},{"period":"6month","weight":0.0371},{"period":"1year","weight":0.2018},{"period":"ytd","weight":0.0358}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"常州千红生化制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"74524人(较上一季度增加2.43%)","perCapita":"12630股","listingDate":"2011-02-18","address":"江苏省常州市新北区云河路518号","registeredCapital":"127980万元","survey":" 常州千红生化制药股份有限公司的主营业务是生物医药品的研发、生产和销售。公司的主要产品是常生千红、千红怡诺、千红怡达、千红怡那、怡开、千红怡美、常生、千红怡甘。","listedPrice":32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"千红制药,002550,千红制药股票,千红制药股票老虎,千红制药股票老虎国际,千红制药行情,千红制药股票行情,千红制药股价,千红制药股市,千红制药股票价格,千红制药股票交易,千红制药股票购买,千红制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}